What question did this study set out to answer?

To determine the feasibility of a multicenter prospective study evaluating neurocognitive function in patients with immune thrombotic thrombocytopenic purpura in clinical remission and to investigate novel biomarkers of neurological injury.

January 22, 2025Journal of Clinical MedicineOpen Access

Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura

View Full Paper

Ask AI

Bookmark

Authors

ABAaron BoothbyUniversity of Washington MEMichael D. EvansUniversity of Minnesota SYShangbin YangBeijing University of Technology

Discussion

Member takes

Implication

Prospective cohort study reveals soluble thrombomodulin correlates with cognitive deficits in immune TTP survivors, highlighting its utility as a biomarker for ongoing brain injury.

Key Points

To determine the feasibility of a multicenter prospective study evaluating neurocognitive function in patients with immune thrombotic thrombocytopenic purpura in clinical remission and to investigate novel biomarkers of neurological injury.
Multicenter prospective longitudinal study conducted across three USTMA consortium sites between 2019 and 2022 with a 24-month follow-up.
Enrolled N=38 patients with immune thrombotic thrombocytopenic purpura in remission to undergo longitudinal clinical, neurocognitive, and biomarker evaluations, including ADAMTS13 activity and soluble thrombomodulin (CD141).
A total of 31 of 38 enrolled participants (81.6%) completed 24-month evaluations, demonstrating high baseline prevalence of headaches (55%), anxiety (47%), and depression (45%).
Participants showed measurable baseline deficits in immediate memory and visuospatial abilities, which remained stable without significant change across the 2-year study window.
Cognitive impairment demonstrated no significant association with ADAMTS13 activity, but correlated significantly with elevated concentrations of soluble thrombomodulin (CD141).

Cite This Study

Boothby et al. (2025) studied this question.

synapsesocial.com/papers/6a1d2d0b1c2cbcb15c5de5d8 https://doi.org/10.3390/jcm14030694

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study reveals soluble thrombomodulin correlates with cognitive deficits in immune TTP survivors, highlighting its utility as a biomarker for ongoing brain injury.

Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura

Discussion

Member takes

Implication

Key Points

Cite This Study

Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider